News & Updates

Treatment with sitravatinib plus nivolumab (sitra + nivo) results in numerically longer median overall survival (OS), albeit statistically nonsignificant, in patients with advanced nonsquamous nonsmall-cell lung cancer (NSCLC) compared with docetaxel, a study has shown.

Third-line treatment with sacituzumab govitecan works better than the physician’s treatment of choice in metastatic triple-negative breast cancer (mTNBC), an invasive histologic subtype with a poor prognosis and rapid progression, as shown in a recent study.

Recurrence-free survival (RFS) is significantly longer with erdafitinib treatment than with intravesical chemotherapy in patients with papillary-only, high-risk nonmuscle-invasive bladder cancer (NMIBC) who had disease recurrence after bacillus Calmette–Guérin (BCG) therapy and were ineligible for radical cystectomy, according to a study.

Amivantamab plus chemotherapy with or without lazertinib results in longer progression-free survival (PFS), as well as intracranial PFS, compared with chemotherapy alone in patients with epidermal growth factor receptor (EGFR)-mutated advanced nonsmall-cell lung cancer (NSCLC) who had disease progression on or after osimertinib, results of the phase III MARIPOSA-2 study have shown.

The addition of internal mammary nodal irradiation (IMNI) in the treatment of breast cancer leads to better overall survival (OS), disease-free survival (DFS), distant metastasis-free survival (DMFS), and lower breast cancer mortality (BCM), reveals a study. In addition, patients with pN+ and medial/central tumour location achieved the best OS from IMNI.

A 52-week course of intensified androgen-deprivation therapy (ADT) appears to extend prostate-specific antigen progression-free survival (PSA-PFS) in patients with biochemically recurrent prostate cancer (BRPC) compared with ADT alone, without prolonging time to testosterone recovery, according to the phase III open-label PRESTO trial.

Noncontrast-enhanced magnetic resonance imaging (NCEMRI) demonstrates superiority over ultrasonography (US) for the surveillance of hepatocellular carcinoma (HCC) in at-risk populations, although this strategy is more expensive than US, according to a Singapore study.